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doi:10.1016/j.ejvs.2010.04.011Abstract Objectives and design: To establish whether in diabetic patients with peripheral
artery obstructive disease (PAOD) vasa vasorum (vv) neoangiogenesis is altered with increased
arterial damage.
Materials: Thirty-three patients with PAOD and critical lower limb ischaemia, 22 with type II
diabetes.
Methods: Immunohistochemistry for endothelial cell markers (CD34 and von Willebrand
Factor); real-time reverse transcription polymerase chain reaction (RT-PCR) to quantify arte-
rial wall expression of vascular endothelial growth factor (VEGF); enzyme-linked immunosor-
bent assay (ELISA) to assess blood VEGF; flow cytometry to detect circulating endothelial
cells (CECs).
Results: Patients with PAOD and diabetes have a higher frequency (60% vs. 45%) of advanced
atherosclerotic lesions and a significant reduction (pZ 0.0003) in CD34þ capillaries in the arte-
rial media. Adventitial neoangiogenesis was increased equally (CD34þ and vWFþ) in all
patients. Likewise, all patients have increased CEC and VEGF concentration in the blood as
well as in-situ VEGF transcript expression.
Conclusions: Patients with PAOD have remarkable arterial damage despite increased in-situ
and circulating expression of the pro-angiogenic VEGF; a dysfunctional vv angiogenesis wascular Surgery, Department of Specialistic Surgical and Anaestesiological Sciences, S. Orsola-Malpighi
Massarenti, 9 Bld 5, 40126 Bologna, Italy. Tel.: þ39 051 6363522; fax: þ39 051 306861.
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366 C. Orrico et al.seen in diabetics which also showed a higher frequency of parietal damage; it is suggested that
in diabetic arterial wall, injury is worsened by vv inability to finalise an effective VEGF-driven
arterial wall neoangiogenesis.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.One of the most dramatic consequences of peripheral
arterial obstructive disease (PAOD) is the critical lower limb
ischaemia (CLI), a clinical condition often followed by the
onset of gangrene and subsequent major amputation. This
condition is greatly enhanced by the presence of diabetes.1
Diabetic arteriopathy is characterised by arterial nar-
rowing due to the rapid progression of atherosclerosis;2
blood endothelial progenitor cells (EPCs) numeric deple-
tion is also observed as well as their functional impairment
with reduced adhesion, migration and incorporation into
tubular structures.3e5 Moreover, an increased presence of
mature circulating endothelial cells (CECs) has been
reported in conditions associated with arterial injury, these
cells representing the straight evidence of endothelial
damage in the intima.6,7
In PAOD, neoangiogenesis plays a key role when exposed
to hypoxia, and resident vascular cells are activated and
release growth factors. The vascular endothelial growth
factor (VEGF) is essential in the regulation of neoangio-
genesis; through binding to its cognate receptor, VEGF
promotes a multistep process which ends with endothelial
cell (EC) differentiation into mature blood vessels.8,9
VEGF also contributes to target EPCs in the injured sites
where they synergistically co-operate with resident cells in
promoting effective angiogenesis and arteriogenesis.10
Recently, a subset of EPCs has been found within the
arterial wall; these resident EPCs are located in corre-
spondence with the vasa vasorum plexus in the human
arterial wall;11,12 vasa vasorum are supposed to contribute
to vascular wall homeostasis during adult life and are
known to respond dynamically to risk factors for athero-
sclerosis, such as hypercholesterolaemia and hyperten-
sion;13 the role of vasa vasorum in diabetic arteriopathy
remains quite unexplored.
In this study we confirm our hypothesis that, in diabetic
patientswith PAOD and CLI, vasa vasorumare unable to carry
on an effective arterial wall neoangiogenesis; in-situ altered
angiogenesismay contribute to accelerated parietal damage
commonly seen in diabetic patients. For this purpose, we
studied ‘in-situ’ expression of the two endothelial markers,
CD34 and von Willebrand Factor (vWF); the severity of pari-
etal damage, by means of histopathological evaluation and
flow cytometry assessment of CEC number; in-situ and
circulating expression of the pro-angiogenic VEGF.
Materials and methods
Patients
Thirty-three patients with PAOD and CLI were recruited
from the Vascular Surgery Unit of the S. Orsola-Malpighi
Hospital of Bologna, after obtaining the approval of the
ethics committee. For flow cytometer, serological and
molecular studies, healthy subjects (n Z 29) and multi-
organ donors (n Z 3) were selected as controls,respectively, from the Transfusion Centre and the Cardio-
vascular Tissues Bank of the S. Orsola-Malpighi Hospital. For
histopathological evaluation and immunohistochemical
analysis control, femoral arteries (n Z 10) were recovered
from the Surgical Pathology’s archive, Department of
Haematology, Oncology and Laboratory Medicine, S.Orsola-
Malpighi Hospital.
The diagnosis of peripheral arteriopathy was made
considering not only the vascular health conditions but also
risk factors such as smoke, diabetes mellitus, hypertension,
hyperlipidaemia and related pathologies such as chronic
renal insufficiency (IRC), ischaemic heart disease, cere-
brovascular insufficiency (ICV) and chronic obstructive
pulmonary disease (COPD). PAOD clinical stage was estab-
lished according to Fontaine-Leriche and Texas University
classifications; arterial lesion topography was evaluated by
means of Doppler ultrasonography, with or without angi-
ography. Once the severity of the disease and the concrete
risk of lower limb amputation were confirmed, patients
underwent surgical revascularisation. During surgery, arte-
rial wall fragments were taken from the proximal anasto-
mosis of the bypass, and destined to histopathological,
immunohistochemical and molecular analyses. Before the
surgical treatment, peripheral blood samples of 40 ml were
taken from each patient and used for flow cytometry and
enzyme-linked immunosorbent assay (ELISA). Our experi-
mental strategy is reported in Diagram I.
Arterial wall histopathological evaluation
Arterial tissue samples were fixed in formalin and
embedded in paraffin; 5-mm-thick haematoxylin- and eosin
(H&E)-stained sections were observed under a light micro-
scope (LM, Olympus CX42), using healthy femoral arteries
recovered from our archive as controls.
Arterial wall lesions were classified according to the
American Heart Association (AHA) classification14 and
grouped as class I (arterial wall samples with type IeIII
lesions) and class II (arterial wall samples with type IVeVI
lesions).
Immunohistochemical assay of arterial wall
neoangiogenesis
Angiogenesis was investigated by immunohistochemical
detection of CD34, a marker of EPCs and microvascular
endothelial cells (ECs), and von Willebrand Factor (vWF),
a protein expressed by mature endothelium. Formalin-fixed
paraffin-embedded 3-mm-thick tissue sections were dew-
axed and rehydrated through decreasing concentrations of
ethanol. Tissue antigenicity was recovered at 1 atm, 120 C
for 20 min. Endogenous peroxidase activity was blocked
with 3% H2O2 in absolute methanol for 10 min at room
temperature (rt). Antigeneantibody reaction was devel-
oped with the NovoLink Polymer Detection Kit (Novocastra,
Diagram I Layout of the experimental strategy.
Vasa Vasorum in Diabetic CLI 367New Castle, UK). Sections were incubated overnight in
a wet chamber at 4 C with monoclonal antibodies against
CD34 (clone QBEnd-10; 1:80; Dako, Copenaghen, Denmark)
and vWF (clone F8/86; 1:50; Dako, Copenaghen, Denmark);
then, sections were incubated with NovoLink Polymer for
30 min at rt, and subsequently with diaminobenzidine
(NovoLink DAB Substrate Buffer) for 30 s. Cell nuclei were
stained with Mayer’s haematoxylin (Sigma Chemicals).
Negative controls were done by omitting incubation with
the primary antibody. The samples were observed in
a computer-assisted light microscope using Image-ProPlus
software (ver. 4.5; MediaCybernetics http://www.mediacy.
com). The evaluation was performed on at least 10 random
fields taken at 20 magnification in each arterial section;
arterial media and adventitia layers were recorded sepa-
rately. Healthy femoral arteries, recovered from our files,
were used as positive controls. Capillary density was eval-
uated as previously described.15
‘In-situ’ VEGF mRNA expression
VEGF mRNA transcripts were quantified in arterial tissue
samples by real-time reverse transcription polymerase chain
reaction (RT-PCR) analysis as previously reported;16 fresh
artery samples recovered from healthy multi-organ donors
were considered controls. The samples were stored at80 C
in RNA-free eppendorf tubes containing a lysis and nucleic
acids purification solution (Lysis Solution 2X), homogenisedthrough centrifugation and, then, digested with proteinase K
(200 mg mle1 of Lysis Solution) overnight at rt. The samples
were centrifuged at 14,000 rpm for 5 min and the aqueous
phase containing RNA was recovered. Total RNA extraction
was performed with an ABI PRISM 6100 Nucleic Acid Pre-
pstation (Applied Biosystems, USA) and its related chemistry.
RNA was dried using a UNIVAPO 100H drier (UNIEQUIP).
Subsequently, the RNA was dissolved in RNAse-free water
(DEPC water) and quantified with a Nanodrop spectropho-
tometer (ND-420, Nanodrop Technology). Nucleic acid quality
was assessed measuring the A260/A280 ratio. Ten microlitres
of total RNA were used for RT reaction following the manu-
facturer’s protocol (High capacity cDNA Archive kit, Applied
Biosystems, USA). cDNA was then amplified through a real-
time PCR. The reaction mix (all reagents from Applied Bio-
systems) contained TaqMan DNA polymerase (TaqMan
Universal PCRMaster Mix 2X ) and primers andprobes for VEGF
(TaqManGeneExpressionAssayseHs00900054_m1-20X );as
housekeeping gene b-actin (TaqMan Gene Expression Assays
e Hs 99999903_m1- 20X -FAM) was used. Real-time PCR was
performedwithanABI PRISM 7000 SequenceDetection System
(Applied Biosystems, USA).
ELISA assay
Serum VEGF concentration was determined with an ELISA
using the Quantikine kit (R&D Systems, Minneapolis, MN,
USA). Donor serum samples were controls. According to the
368 C. Orrico et al.manufacturer’s instructions, samples were pipetted in a 96-
well polystyrene microplate pre-coated with a monoclonal
antibody specific for VEGF; after washing, an enzyme-
linked polyclonal antibody specific for VEGF was added to
the wells. After additional washings, a substrate solution
was layered on each well and a colorimetric reaction
developed. The intensity of colour, which was proportional
to the amount of VEGF bound in the initial step, was
measured using a multiplate spectrophotometer reader at
an optical density of 450 nm.Table 1 Patients’ characteristics, risk factors and
severity of peripheral artery obstructive disease. COPD:
Chronic obstructive pulmonary disease.
Characteristic N %
Age (year)
main SD 71.3 10.8
Range 39e 91
Sex
Male 24 72.7%
Female 9 27.3%
Cardiovascular risk factors
Hypertention 24 72.7%
Smoking 11 33.3%
Hyperlipidemia 16 48.4%
COPD 8 24.2%
Diabetes mellitus 22 66.7%
Coronary artery disease 20 60.6%
Chronic Renal failure 10 30.3%
Cerebrovascular Disease 10 30.3%
Preintervention Leriche-Fontaine Classification
II A e
II B e
III 4 15.4%
IV 29 87.8%
Texas University Classification
I 4 13.7%
I C 3
I D 1
II 3 10.3%
II C 2
II D 1
III 22 76%
III C 6
III D 16Detection of CD146Dcirculating endothelial cells
Flow cytometry was performed on peripheral blood samples
for determining CEC levels. The assay was performed with
the CELLQUANT FF-CD146 Kit (BioCytex, France); healthy
subject blood samples were used as control after informed
consent was obtained. Briefly, CECs were enriched from
whole blood by magnetic nanoparticles coated with CD146.
The enriched samples were stained with FITC-CD45 and PE-
CD146 following the manufacturer’s instructions. CECs were
counted using fluorescent counting beads provided with the
kit. Analysis was performed with an FC500 cytometer
(Beckman Coulter Miami, FL, USA). CECs were defined as
cells with a CD146þ/CD45e phenotype per millilitre.
Statistical analysis
Data have been summarised as appropriate means and stan-
dard deviations, but generally medians and interquartile
ranges (IQRs) were preferred owing to the non-normal distri-
bution of measures. Consequently, for comparisons, non-
parametric tests were performed (ManneWitney U test), and
scatter graphs were used for graphic representations.
Data in nominal or ordinal scale were summarised as
numbers of subjects and percentages, and Fisher’s exact
test or raw OR, ORMH were used for comparisons.
Due to the relatively small number of subjects and of
controls, it was not possible to correct some comparisons
for age and gender; when possible, data were put into
a backward-logistic regression model to calculate a cor-
rected odds ratio (OR) between cases and controls.
Statistical analysis was carried out using SPSS 17.0 (SPSS
Inc., Chicago, IL, USA). A first type error <0.05 was
accepted.
Results
Patients and controls
Patients’ age ranged from 39 to 91 years with a mean value
of 71.3  10.8.
Twenty-two PAOD patients (66.7%), suffering from type
II diabetes, constituted the diabetic PAOD group, and 11
patients (33.3%) were available in the non-diabetic PAOD
control group. Although diabetic subjects were under
hypoglycaemic therapy (85% treated with insulin, 15% with
oral hypoglycaemic agents), they had a mean glycaemic
value (159  76 mg dle1) out of the normality range
(60e110 mg dle1). Patients were distinguished in 24 males(72.7%) and nine females (27.3%), with males being signif-
icantly older than females (p Z 0.044). No statistically
significant difference was revealed for diabetes frequency
in the two genders.
From healthy controls, none of them were suffering from
diabetes. No significant difference was shown between
patients and controls for gender or age.
The prevalence of risk factors and the severity of the
disease for the patients are summarised in Table 1.
Morphological analysis
Diabetic arterial wall compared with non-diabetic one
revealed a higher frequency (60% vs. 45%) of advanced
lesions; such difference was not statistically significant,
particularly when corrected for age and gender. No signif-
icant difference was found between the two groups of
patients (Fig. 1AeD).
Arterial wall neoangiogenesis
Vasa vasorum in the adventitia were lined with vWFþ/
CD34þ ECs; on the contrary, capillaries in the arterial media
predominantly expressed the CD34 surface molecule. When
Figure 1 Patients with PAOD and CLI show histological damage of the arterial wall, greater in the diabetic patients. A) Arterial
wall structure of healthy control subject; B) pathological intimal thickening and C) fibrous cap atheroma seen at the proximal
anastomosis of the bypass; D) diabetic patients present a higher frequency (60% vs 45%) of advanced lesions (type IVeVI); no
significant difference was found between diabetic and non-diabetic patients; on Y axis, in percentage (%) the lesion frequency.
PAOD: peripheral artery obstructive disease; CLI: critical limb ischaemia; L: lumen; arrowheads indicate inner elastic lamina; FC:
fibrous cap; LC: lipid core; V: vessels; d: diabetic patients; nd: non-diabetic patients. 2.5x, original magnification (250 mm, scale
bar) for A), B) and C).
Vasa Vasorum in Diabetic CLI 369compared to healthy controls, quantitative evaluation of
immunohistochemical staining in PAOD patients revealed
a significant increase in adventitial neoangiogenesis, CD34þ
and vWFþ (p Z 0.006 and p Z 0.0001, respectively); no
significant difference was seen between CD34 and vWF
expression in PAOD patient adventitia layer (Fig. 2AeG). In
contrast, in PAOD patient media layer
CD34þ neoangiogenesis was significantly higher than
vWFþ angiogenesis (p Z 0.0001) (Fig. 3AeE); however, the
diabetic group showed a significantly reduced CD34þmedial
neoangiogenesis (p Z 0.0003) when compared to the non-
diabetic control group (Fig. 4AeD).
Arterial wall expression of VEGF mRNA transcripts
Real-time RT-PCR revealed a significantly higher expression
of VEGF mRNA transcripts in PAOD patients than in healthy
controls (p Z 0.016) (Fig. 5A).
The comparison patient-control age-twined confirmed this
significantdifference (pZ0.034), indicating that the increase
of in-situ VEGF expression was related to the peripheral
arteriopathy, but was not influenced by patients’ age.
No significant difference was revealed between diabetic
and non-diabetic patients.
Blood VEGF
Serum VEGF concentration resulted in a significant
increase in all PAOD patients (median 170,775 and IQRfrom 45,91 to 330,778) compared to healthy controls
(median 75,775 and IQR from 12,168 to 147,723)
(pZ 0.036) (Fig. 5B). Such difference was not statistically
significant after comparison of patient-control age-
twined, suggesting an influence of patients’ age on
circulating VEGF level increase in PAOD subjects with
respect to controls. No difference was revealed between
diabetic and non-diabetic patients.
Flow cytometry of circulating endothelial cells
Median values of CECs per millilitre resulted significantly
higher in all PAOD patients (369,5 and IQR from 221,5 to
835) than in control healthy subjects (110 and IQR from 75,5
to 238,5) (p Z 0.0001) (Fig. 5C), with diabetic subjects
presenting by far the highest values. A backward-logistic
regression, performed to correct data for age and gender,
confirmed this significant difference (p Z 0.03), indicating
that the subjects with peripheral arteriopathy, with respect
to healthy subjects, had an increased CEC number in the
peripheral blood, independent of their age and sex. No
significant difference was seen between the two PAOD
populations.
Discussion
Diabetes mellitus represents one of the greatest medical
and socio-economic challenges worldwide17 with the inci-
dence of type II disease already reaching epidemic
Figure 2 Quantitative immunohistochemistry shows a significant increase in adventitial neoangiogenesis (CD34þ and vWFþ) in all
PAOD patients (diabetic and non-diabetic). A), C) and E) immunohistochemical CD34 detection; B), D) and F) immunohistochemical
vWF analysis; G) PAOD patients, when compared to healthy controls, present a significant increase in CD34 and vWF expression in
adventitia layer (p Z 0.006 and p Z 0.0001, respectively); on Y axis, the values are referred to positive areas (mm2) observed for
the two endothelial markers. Ctr: control femoral artery from healthy multi-organ donor; nd: tissues from non-diabetic patients; d:
tissues from diabetic patients. 100x, original magnification (250 mm, scale bar) for A) and B); 25x, original magnification (100 mm,
scale bar) for C) and E); 25x, original magnification (250 mm, scale bar) for D) and F).
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Figure 3 Medial neoangiogenesis: a comparison between CD34 and vWF immunohistochemical expression in all PAOD patients. A)
and C) CD34 detection; B) and D) vWF staining; E) in PAOD patient media layer, CD34þ neoangiogenesis was significantly higher than
vWFþ angiogenesis (p Z 0.0001); on Y axis, the values are referred to positive areas (mm2) observed for the two endothelial
markers. nd: tissues from non-diabetic patients; d: tissues from diabetic patients. 10x, original magnification (100 mm, scale bar)
for A), B), C) and D).
Vasa Vasorum in Diabetic CLI 371proportions.18 Despite the introduction of new therapies,
vascular complications represent the leading cause of
morbidity and mortality in diabetic patients. People with
diabetes have a much higher incidence of coronary artery
disease as well as peripheral artery disease, and cerebro-
vascular disease rather than the general population in part
due to accelerated atherogenesis.17,18 Diabetic vasculop-
athy is characterised by structural changes of large and
small arteries with tissue hypoperfusion and hypoxia,17
involving multiple distal arterial segments.19 At the
macro-vascular level, these changes manifest with the
characteristic intima and mediaethickening, and vessel
rigidity reflecting the altered composition and function of
the arterial wall. The most described features include EC
dysfunction and depletion; smooth muscle cell prolifera-
tion; macrophage infiltration; changes in the extracellular
matrix (ECM) composition; calcium and matrix proteindeposition; and changes in the interaction between circu-
lating cells and ECs.17
Vasa vasorum are considered to play a role in the initi-
ation, progression and complication of atherosclerosis.13 In
large and medium-sized vessels, they provide nutrients and
oxygen to the media layer while removing ‘waste’ catabolic
products. On the other hand, they are thought to facilitate
the entry of pro-inflammatory and pro-atherosclerotic
components into the arterial wall. Further, vasa vasorum
possibly represent the stem cell niche which regulates
vessel wall homeostasis during the adult life.11,12 However,
the role of vasa vasorum in diabetic peripheral arteriopathy
yet remains quite unexplored.
In this study, a significant damage of the arterial wall with
vascular endothelium injury has been documented in PAOD
patients; CEC quantitative flow cytometry assay demon-
strated that CD146 positive circulating ECs are significantly
Figure 4 A), B) and C) CD34þ capillaries in the media layer of PAOD patients (10x, original magnification; 100 mm, scale bar); D)
diabetic subjects, when compared to non diabetics, showed a significant reduction in CD34þ medial neoangiogenesis (pZ 0.0003);
on Y axis, the values are referred to areas (mm2) positive for CD34. nd: tissues from non-diabetic patients; d: tissues from diabetic
patients.
372 C. Orrico et al.raised in the peripheral blood of all PAOD patients, in an
independent way from patients’ age, and with diabetic
subjects presenting by far the highest values. The flow
cytometry result is consistent with histopathological investi-
gation that revealed a higher frequency of advanced lesions in
the arterial wall of diabetics. An increase in CEC number has
been described in different pathological settings charac-
terised by vascular damage.6,7 The prolonged endothelial
insult is believed to be responsible for sloughing off the vessel
wall that releases in the peripheral blood circulating ECs; as
previously reported,7 CEC appearance in the blood is theconsequence of a disease process that irreversibly damages
the endothelium. Overall, the flow cytometry and histopath-
ological results confirm that the presence of diabetes is
associated with an incremental damage of the arterial wall.
Metabolic, humoral and haemodynamic factors, all
contribute to vascular injury in diabetes through growth
factor and cytokine arterial wall modulation; among the
growth factors, VEGF has attracted much attention because
of its key role in the pathological neovascularisation that
characterises diabetic microangiopathy; VEGF is a major
mediator of neoangiogenesis in physiological and
Figure 5 A) VEGF mRNA transcripts are up-regulated in the arterial wall of PAOD patients (p Z 0.016); B) the pro-angiogenic
VEGF protein is also significantly increased in the blood circulation (p Z 0.036); C) CEC levels are significantly higher in all PAOD
patients than in control healthy subjects (pZ 0.0001). VEGF: vascular endothelial growth factor; CEC: circulating endothelial cells.
Vasa Vasorum in Diabetic CLI 373pathological conditions with crucial roles in developmental
blood vessel formation and regulation of hypoxia-induced
tissue angiogenesis. In diabetes, there is an impairment of
the endogenous reperfusion mechanism with limited
generation of arterial collaterals and new vessels by arte-
riogenesis and angiogenesis;17 thus, a significant modula-
tion of VEGF is expected in the context of PAOD with CLI.
In response to tissue ischaemia, the target organs
increase VEGF transcript and protein levels.20 Accordingly,
in this study, ELISA assay revealed a significant increase of
serum VEGF concentration in all patients with CLI; this
increase could be influenced by patients’ age and therefore
be an expression of a generalised vascular damage as
expected in our patient population. A differential regula-
tion of VEGF and its receptors has been observed between
highly vascularised tissues, such as the retina, and cardiac
tissues;21 in particular, an increased VEGF mRNA expression
was seen in the retina from diabetic rats, and related to the
concomitant capillary leakage and excessive neo-
vascularisation, while a decreased expression was found in
ventricles from diabetic patients, and related to inade-
quate collateral formation in the diabetic myocardium.
However, the VEGF role in other vascular sites in diabetes is
not well characterised; low levels of constitutive VEGF
mRNA in medium to large arteries have been observed in
vivo in humans, and this expression was found restricted to
vascular smooth muscle cells;22 because of VEGF role in
promoting ‛in-situ’ angiogenesis, various stimuli relevant to
the diabetic context have been reported to increase the
vascular expression of VEGF including hypoxia, Advanced
Glycation End-products (AGE’s) and elevated glucose
concentrations.23 Here, we found that, when compared to
controls, the femoral arterial wall of PAOD patients
contains a significant raised expression of VEGF transcripts;
this increase did not appear to be related to patients’ age,
rather influenced by peripheral arteriopathy.
VEGF induces neoangiogenesis by acting on resident
vascular cells as well as by promoting the release of bone-
marrow-derived EPCs in the circulation; EPCs are believed
to localise specifically at sites of ischaemia where they
contribute to blood vessel growth.19,24 In the presence of
diabetes, EPCs are functionally impaired3e5 and show
defective migration in response to VEGF and hypoxia-
regulated factors, such as the stromal-derived factor, on
which these cells depend for their recruitment to ischaemic
sites.25,26 Further, a significant decrease in the number of
EPC has also been described in patients with diabetes and
PAOD, especially in the presence of ischaemic footlesions.4,5 In the present study, we found a significant
increase in arterial wall neoangiogenesis in all PAOD
patients, and this increase was unrelated to the presence of
diabetes; therefore, we believe that in the present clinical
context, the contribution of bone-marrow EPCs to arterial
wall angiogenesis is of limited importance.
Immunohistochemical analysis showed a dense network
of thin-walled capillaries, which intensely expressed vWF;
the vascular network extended from the outer media
throughout the adventitia layer; this anatomical location
and morphology strongly suggest a neoangiogenic response
of the vasa vasorum system. In healthy humans, only vessels
more than 0.5 mm lumen diameter do have vasa vasorum,
which contribute to deliver nutrients and oxygen to the
media; moreover, they respond dynamically to the vessel
requirements by undergoing vasodilatation and vasocon-
striction as well as increase in number.13 An intriguing
finding is that EPCs were also discovered in the adult
vascular wall in humans, indicating that the arterial wall is
not only a destination but also a source of cells that have
regenerative potential.27 Ingram et al.28 reported the
existence of vessel-wall-derived EPCs without describing an
exact parietal localisation of these cells. A ‘vasculogenic
zone’, where EPCs reside, was identified in the wall of large
and mid-sized blood vessels; this zone, located at the
border between the medial and the adventitial layers,11,12
is believed to act as a source of progenitors for postnatal
vasculogenesis,11 and anatomically corresponds to the vasa
vasorum location.
Immunohistochemical analysis did not reveal a signifi-
cant difference between CD34þ and vWFþ adventitial
neoangiogenesis: the expression of these endothelial
markers was quite similar, showing a significant increase in
all PAOD patients with respect to healthy controls.
Conversely, the media expression of CD34þ capillaries
resulted significantly higher than vWFþ one, in all PAOD
patients compared to controls; however, diabetics, when
compared to non-diabetic group, showed a significantly
decreased CD34þ medial angiogenesis, thus suggesting
a dysfunctional angiogenesis in such patients. CD34 is
a member of single-pass transmembrane sialomucin
proteins, which is specifically expressed by EPCs, ECs and
haematopoietic stem cells;29 the observation that neo-
vessels in the media predominantly expressed CD34 is an
evidence of their immature condition.
These results suggest that in diabetic milieu, vasa
vasorum are unable to perform an effective VEGF-driven
angiogenesis; the possibility that this failure may be
374 C. Orrico et al.a consequence of resident EPC injury needs further inves-
tigation; here, a decreased neoangiogenesis in the media of
diabetic PAOD patients was found; it is speculated that the
disturbed angiogenesis could determine a reduced perfu-
sion of the arterial wall, resulting in increased arterial wall
damage that can contribute to the accelerated athero-
sclerosis in diabetes.
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